{"preliminary_commentary":{"by_channel":{"bluesky_thread":2,"x_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT07229417","nct_id":"NCT07229417","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct07229417. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants found to be eligible to take part in this study, you will receive ivonescimab by vein over about 60 minutes on Day 1 of each 21-day cycle.","label":"Phase II: Treatment with Ivonescimab","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2029-09-30","type":"ESTIMATED"},"conditions":["Metastatic Endocrine Refractory","Triple Negative Invasive Lobular Carcinoma"],"enrollment":{"count":29,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Ivonescimab","otherNames":[],"type":"DRUG"}],"last_update":"2026-07-29","lead_sponsor":"M.D. Anderson Cancer Center","official_title":"IvoLoC Trial: A Phase II Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-09-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Safety and adverse events (AEs)","timeFrame":"an average of 1 year"}],"references":[],"start_date":{"date":"2025-10-22","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma","url":"https://clinicaltrials.gov/study/NCT07229417"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct07229417"}